Next report date
Report period
Q1 2024
EPS estimate
−0.51EUR
Revenue estimate
52.27 MEUR
−3.43EUR
−293.53 MEUR
212.04 MEUR
95.22 M
About REVANCE THERAPEUTICS INC
Sector
CEO
Mark J. Foley
Headquarters
Nashville
Website
Employees (FY)
597
Founded
1999
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RTI is 3.10 EUR — it has increased by 0.65% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange REVANCE THERAPEUTICS INC stocks are traded under the ticker RTI.
REVANCE THERAPEUTICS INC is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
RTI stock is 0.65% volatile and has beta coefficient of 1.93. Check out the list of the most volatile stocks — is REVANCE THERAPEUTICS INC there?
RTI earnings for the last quarter are −0.37 EUR per share, whereas the estimation was −0.66 EUR resulting in a 44.16% surprise. The estimated earnings for the next quarter are −0.59 EUR per share. See more details about REVANCE THERAPEUTICS INC earnings.
REVANCE THERAPEUTICS INC revenue for the last quarter amounts to 53.71 M EUR despite the estimated figure of 55.25 M EUR. In the next quarter revenue is expected to reach 56.28 M EUR.
Yes, you can track REVANCE THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
RTI stock has fallen by 12.43% compared to the previous week, the month change is a 30.80% fall, over the last year REVANCE THERAPEUTICS INC has showed a 89.08% decrease.
RTI net income for the last quarter is −50.46 M EUR, while the quarter before that showed −133.55 M EUR of net income which accounts for 62.21% change. Track more REVANCE THERAPEUTICS INC financial stats to get the full picture.
Today REVANCE THERAPEUTICS INC has the market capitalization of 319.63 M, it has decreased by 4.76% over the last week.
No, RTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REVANCE THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 597.00 employees. See our rating of the largest employees — is REVANCE THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REVANCE THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REVANCE THERAPEUTICS INC stock shows the sell signal. See more of REVANCE THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on REVANCE THERAPEUTICS INC future price: according to them, RTI price has a max estimate of 27.92 EUR and a min estimate of 5.58 EUR. Read a more detailed REVANCE THERAPEUTICS INC forecast: see what analysts think of REVANCE THERAPEUTICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REVANCE THERAPEUTICS INC EBITDA is −187.57 M EUR, and current EBITDA margin is −88.46%. See more stats in REVANCE THERAPEUTICS INC financial statements.